Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET)
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Carcinoid tumour; Neuroendocrine carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CABINET
- 30 Jul 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 Planned initiation date changed from 12 Jun 2018 to 16 Jul 2018.
- 27 Dec 2017 New trial record